Autres langues Hepion Pharmaceuticals, Inc.

Actions

HEPA

US4268973025

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
1,08 ^USD	+5,88 %		+3,85 %	-66,67 %

21/05	Hepion Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
19/04	Hepion Pharmaceuticals, Inc. lance les activités de réduction progressive des activités dans l'essai de phase 2b " ASCEND-NASH ". ASCEND-NASH	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	21/05
Sector Update: Health Care Stocks Increase Late Afternoon	22/04
Sector Update: Health Care	22/04
Top Midday Decliners	22/04
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial	22/04
North American Morning Briefing: Stock Futures Rise, Busy Week of Earnings Ahead	22/04
Hepion Pharmaceuticals Starts Wind-Down Activities in Phase 2b ASCEND-NASH Trial	19/04
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial	19/04
Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ?ASCEND-NASH? Trial	19/04
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell	06/03
Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors	06/03
Hepion Pharmaceuticals, Inc. Announces Board Changes	20/02
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds	16/02
Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors	07/02
Hepion Pharmaceuticals to Present at NASH-TAG 2024	03/01
North American Morning Briefing : Futures Pause -2-	08/12
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value	07/12
Hepion Pharmaceuticals Approves Restructuring Plan to Preserve Capital, Launches Strategic Review Process	07/12
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes	07/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Hepion Pharmaceuticals, Inc.

Actions

HEPA

US4268973025

Autres langues

Filtres